Current Drug Delivery (Curr Drug Deliv)

Publisher: Bentham Science Publishers

Journal description

The aim of Current Drug Delivery is to publish peer-reviewed articles, short communications, short and in-depth reviews in the rapidly developing field of drug delivery. Modern drug research aims to build in delivery properties of a drug at the design phase, however in many cases this ideal cannot be met and the development of delivery systems becomes as important as the development as the drugs themselves. The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance. The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.

Current impact factor: 2.25

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.248

Additional details

5-year impact 0.00
Cited half-life 0.00
Immediacy index 0.00
Eigenfactor 0.00
Article influence 0.00
Website Current Drug Delivery website
Other titles Current drug delivery (Online)
ISSN 1875-5704
OCLC 60333013
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Bentham Science Publishers

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Author's pre-print on author's personal website, institutional repository and open access repository
    • Author's post-print on author's personal website, institutional repository, open access repository, PubMed Central and arXiv
    • Non-Commercial
    • Published source must be acknowledged
    • Must link to journal home page with DOI
    • Publisher's version/PDF cannot be used
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: In our previously study, a novel liver-targeting interferon (IFN-CSP) combining IFN α2b with plasmodiumregion I-plus peptide was successfully designed and prepared withEscherichia coli expression systems. The purified IFN-CSP showed anti-HBV activity and liver-targeting potentiality. The present investigation was designed to investigate the molecular mechanisms responsible for liver targeting of IFN-CSP. Studies of hepatocytes demonstrated that the localization of IFN-CSP in hepatocytes was the plasma membrane. Studies of liver tissue slices showed that IFN-CSP bound to liver tissue in a pattern similar to the distribution of heparan sulfate proteoglycan (HSPG) immunoreactivity. Pretreatment of hepatocytes and liver slices with heparinase reduced the binding of IFN-CSP to HepG2.2.15 cells and liver slices. Coincubation of IFN-CSP with heparin markedly inhibited IFN-CSP binding to HepG2.2.15 cells and liver slices. These results indicate that the molecular mechanisms responsible for IFN-CSP targeting involve binding to HSPG of hepatocytes and liver.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Development of stimuli-sensitive hydrogels for the delivery of drug involves the development of matrices that are glucose-sensitive and have strong sensing properties so that the developed system can sense the level of glucose and release the medicament in response to blood glucose level. In the present study an attempt has been made to develop a glucose sensitive hydrogel system which modulates the release of an anti-diabetic drug in response to the blood glucose level in the body. The hydrogel system was prepared by gas foaming technique using chitosan and polyvinyl alcohol (PVA) as polymer and glutaraldehyde as cross-linking agent. Metformin was used as a drug candidate because of its short biological half life (6.25±0.5 hrs). The prepared glucose sensitive hydrogel system has characterized using different parameters. It was observed that hydrogel swelled and deswelled reversibly depending on the pH and glucose sensitivity of the medium and has suitable mechanical properties. In-vitro results showed that the enzymatically immobilized hydrogel was sensitive to both pH and glucose for effective release of drug. It was found that higher the concentration of glucose in the medium, higher the amount of drug released from the hydrogel. In vivo results showed that glucose oxidase leads to reduction in blood glucose level in response to variable glucose concentration in the body thus achieving the desired therapeutic levels in the body . The present study showed that glucose sensitive hydrogels not only are efficient in controlling the physiological blood glucose level but also provide for a sustained and controlled release of drugs having short biological half life.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The object of the current study was to prepare novel microemulsion formulations of aprotinin for parenteral delivery and to compare in vitro characteristics and release behaviour of different Technetium-99m (99mTc)-Aprotinin loaded microemulsion formulations. In addition, cytotoxicity of microemulsion formulation was evaluated with cell culture studies on human immortalized pancreatic duct epithelial-like cells. For this aim, firstly, pseudo-ternary phase diagrams were plotted to detect the formulation region and optimal microemulsions were characterized for their thermodynamic stability, conductivity, particle size, zeta potential, viscosity, pH and in vitro release properties. For in vitro release studies aprotinin was labelled with 99mTc and labelling efficiency, radiochemical purity and stability of the radiolabeled complex were determined by several chromatography techniques. Radiolabeling efficiency of 99mTc-Aprotinin was found over than 90% without any significant changes up to 6 hours after labelling at room temperature. After that, in vitro release studies of 99mTc-Aprotinin loaded microemulsions were performed with two different methods; dissolution from diffusion cells and dialysis bags. Both methods showed that release rate of 99mTc-Aprotinin from microemulsion could be controlled by microemulsion formulations. Drug release from the optimized microemulsion formulations was found lower compared to drug solution at the end of six hours. According to stability studies, the optimized formulation was found to be stable over a period of 12 months. Also, human immortalized pancreatic duct epithelial-like cells were used to evaluate the cytotoxicity of optimum formulation. Developed microemulsion did not reveal cytotoxicity. In conclusion the present study indicated that the M1-APT microemulsion is appropriate for intravenous application of aprotinin.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to investigate Quality by Design (QbD) principles for the preparation of hydrogel products to prove both the practicability and the utility of executing QbD concepts to hydrogel based controlled release systems. Product and process understanding will helps to decrease the variability of critical material and process parameters, which gives quality product output and reduce the risk. To identify and control the variability in process and material attributes, risk criticality assessment approach was utilize. It also helps to identify the effect of these attributes on Critical Quality Attributes (CQAs). This study includes the identification of the target product profiles (TPPs) from literature for prior prepared batches, as well as the CQAs, which were further helps in selection of experimental design. Potential risk factors were identified using fishbone diagram and screened by risk assessment and optimized by 3-level 2-factor experimental design with centre points in triplicate, to analyse the precision of the target process. This optimized formulation was further characterized by gelling time, gelling temperature, rheological parameters, in-vitro biodegradation and in-vitro drug release Design space was created using experimental design tool which gives the control space and working within this control space reduce all the failure modes below risk level. In conclusion, QbD approach with Quality Risk Management (QRM) tool provided potent and effectual pyramid to enhance the quality into hydrogel.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antisense technology has been a promising strategy for combating infectious diseases caused by multi-drug resistant bacterial strains, but the poor cellular uptake and transfection efficiency of these "antisense antibiotics" is strangling the development of antisense RNA therapeutics. This study was aimed at evaluating the cellular uptake characteristics and transfection efficiency of antisense phosphorothioateoligodeoxyribonucleotides (PS-ODN) in bacterial cells mediated by LipofectamineTM 2000 (LF2000). The size and surface morphology of LF2000/ODN nanoparticle were determined by dynamic light scattering and transmission electron microscope. Then the characteristics of cellular uptake was studied by flow cytometry analysis, and antibacterial efficacy of LF2000/ODN nanoparticle targeting rpoD, an RNA polymerase primary σ70, was tested by growth curve assay and RT-PCR. And the results showed the size of the spherical nanoparticle obtained was about 120 nm with a zeta potential about -5 mV, and the encapsulation efficiency of PS-ODN was about 95%. The cellular uptake efficiencies of LF2000/ODN nanoparticle by extended-spectrum β-lactamase-producing Escherichia coli (ESBLs-E. coli) and E. coli were 40.1% and 48.5% in a time-independent manner, while 76.7% and 79.3% by meticillin-resistant Staphylococcus aureus(MRSA) and S. aureusin a time-dependent manner. Interestingly, the uptake process was not impacted by the incubation temperature. After being incubated with LF2000/ODN, the growth of tested bacteria were significantly retarded, and the transcription of rpoDwas inhibited. Our research not only provided an experimental basis for further studies on delivery systems of antisense antibiotics, but also hinted a novel cellular uptake mechanism of nanoparticle.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Choroidal neovascularization (CNV), also known as subretinal neovascularization, causes serious damage to the central vision as it happens more commonly in macula. The most important factor involved in angiogenesis is vascular endothelial growth factor (VEGF). By an RNAi technique, VEGF gene knockdown can be used to treat CNV. PEG-conjugated poly (amidoamine) (PEG-PAMAM) dendrimers as a new type of synthetic polymers are very promisingto begene delivery carriers. To investigate siRNA delivery efficacy of PEG-PAMAM dendrimers, we prepared dendriplexes of PEG-PAMAM dendrimers with a fluorescence-labelled siRNA (PEG-PAMAM/FAM siRNA) or VEGF siRNA (PEG-PAMAM/VEGF siRNA), and studied transfection and downregulation efficacy of the dendriplexes in a cobalt chloride (CoCl2)-induced neovascularization model in retinal vascular endothelial cells(RF/6A). Our results demonstrate that PEG-PAMAM dendrimers had significantly higher transfection efficiency to FAM siRNA than a commercial transfection reagent PEI (1.4-fold,P<0.001) measured by flow cytometry. Compared to the PEI/VEGF siRNA polyplexes, the dendriplexes of the PEG-PAMAM/VEGF siRNA more significantly downregulated VEGF gene expression (P < 0.01) atboth mRNA and protein expression level. A tube formation assay also proved that the PEG-PAMAM/VEGF siRNA dendriplexes more significantly inhibited vascular-like formation than PEI/VEGF siRNA did (P < 0.001) in RF/6A.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Implant has become an inevitable part of orthopaedic surgeries. However, implant associated infection remains a major problem for the orthopaedic surgeons and researchers. This review focuses on current options available for prevention of implant associated infection, their drawbacks and future promising applications of nanotechnology-based approaches. Novel drug delivery systems comprising microparticles, nanoparticles and liposomes, implant surface modification, nanocoating and use of magnetic nanomaterial have also found advantageous. Nanobiotechnology has shown remarkable progress in recent years especially in biomaterials, diagnostics, and drug delivery system. Although several applications of nanobiotechnology in orthopaedics have been described, few have elaborated its role in prevention of implant related infection in orthopaedics. Novel "smart" drug delivery systems that release antibiotics locally in response to stimuli such as pH, temperature, enzymes or antigens; biomaterial technology to modify implant surface on a nanoscale can prevent infection by inhibiting bacterial adhesion and propagation at the surgical site. Similarly, nanotechnology based biological approaches such as gene therapy to neutralize the bacterial virulence and biomolecules to inhibit the quorum sensing adhesion of bacteria and disruption of biofilms can be used effectively to prevent implant related bacterial infection.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chemical penetration enhancers (CPEs), which are also referred to as sorption promoters or accelerants have several advantages in transdermal drug delivery. These are painlessness, noninvasiveness and the capacity to increase in transdermal flux in comparison with passivediffusion. Several investigators have used a number of chemical enhancers to demonstrate theseimportant properties. Studies have also been carried out to have a better understanding of the mechanisms of penetration enhancement. It has been postulated that these compounds can enhancetransdermal drug delivery by perturbing the stratum corneum, increasing partition coefficient orincreasing solubility. In this paper, several compounds used in facilitating percutaneous penetration ofdrugs have been described and the potential of using them for transdermal drug delivery highlighted.Special attention has been paid to cell-penetrating proteins (protein transduction domains) as well asskin penetrating peptides. Ironically, these are substances that possess high molecular weightthemselves but are capable of creating pores through which drugs can penetrate into and through theskin. Concerns relating to irritation and cytotoxicity and efforts to overcome them are discussed.
    Current Drug Delivery 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this Study drug (paclitaxel)-loaded nanoparticles of poly hydroxybutyrate-polyethylene glycol-folic acid (PHB-PEG-FOL) were prepared by using an oil-in-water (O/W) emulsion-solvent evaporation method. The functionalization and conjugation steps in the chemical synthesis were confirmed using Fourier transform infrared (FTIR) and nuclear magnetic resonance tests (1H NMR). Morphology of nanoparticles was evaluated by scanning electron microscopy (SEM). Nanoparticles were characterized by particle size analyzer.Between two samples containing drug, the lower doses showed more homogeneous distribution, and the lowest aggregation.The drug release profiles showed a two-phase release including initial rapid release and a continuous release. MG63 cells were used to evaluate cytotoxicity. The cytotoxicity of PHB-PEG-FOL nanoparticles with drug against cancer cells was much higher and longer than free drug sample. These nanoparticles were successfully synthesized as a novel system for targeted drug delivery against cancer cells.
    Current Drug Delivery 08/2015;
  • Current Drug Delivery 08/2015; Accepted for publication.
  • Current Drug Delivery 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the present research is to prepare stable nano suspensions of Valsartan (VAL) with high solubility and dissolution. VAL is an orally administered anti-hypertensive drug with lower bio-availability of 25%, this is attributed to its lower aqueous solubility (0.082 mg/ml). VAL nano suspensions were prepared by using a bottom-up precipitation technique using five level full factorial central composite design (CCD). The optimized nano formulations NS21, NS22, NS23 showed the particle size of 268.42 ± 8.99, 288.3 ± 11.32, 293.46 ± 6.92 nm, zeta potential of 20.89 ± 0.79, 26.01 ±1.02, 21.34 ± 0.43 mVs and the dissolution efficiency of 93.10 ± 1.459, 91.84 ± 1.419, 89.47 ± 0.644 % respectively. SEM & AFM studies represent the formation of fine irregularly shaped particles with smooth surfaces on nanosization. X-rd studies confirmed the physical state conversion of crystalline drug into amorphous form. Drug excipient compatibility was studied using differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FT-IR). The investigation pragmatic the solubility and dissolution efficiency of VAL in nanosuspension was significantly higher when compared with its pure form. Finally, it is concluded that, nanosuspension approach could be an ideal, promising approach to increase the solubility and dissolution of BCS-II drugs like Valsartan.
    Current Drug Delivery 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we evaluated different strategies to optimize the percutaneous absorption of niacinamide (NA) and soy phytosterols (FITO) by making use of solid lipid nanoparticles (SLN) and penetration enhancers, such as the hydrogenated lecithin. The evaluation of the skin permeation of NA and FITO has been effected in vitro using excised human skin (i.e., stratum corneum-epidermis or SCE). Furthermore, we evaluated the in vivo effect that NA and FITO has on skin barrier recovery after the topical application; using the extent of methyl nicotinate (MN)-induced erythema in damaged skin as a parameter to determine the rate of stratum corneum recovery. Results pointed out the importance of these strategies as valid tools for NA and FITO topical delivery. In fact, soy lecithin based formulations were able to increase the percutaneous absorption of the two active ingredients, while SLN guaranteed an interesting delayed and sustained release of FITO. In vivo evaluation showed clearly that the formulation containing both the actives (NA and FITO) is able to recover about 95% of skin barrier integrity eight days after tape stripping. This effect is probably due to the "synergistic effect" of NA and FITO.
    Current Drug Delivery 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present research investigates development and in vivo evaluation of oral diacerein formulations with quicker and complete absorption. In vivo, diacerein gets completely metabolized to its active metabolite rhein in gut and liver, which is the only analyte detected in plasma. Incomplete absorption of diacerein from the formulation leads to colonic availability of rhein, which is associated with increased laxative effect as one of the side effects of diacerein therapy. Thus solubility improved immediate release formulation (IR) and a gastroretentive formulation (GR) was designed to achieve rapid absorption preferentially through upper part of gastro-intestinal tract; thus controlling the amount of rhein reaching to colon and minimizing the associated increased laxative effect. In vitro drug release studies of the developed formulations revealed faster and complete release of diacerein from IR and GR formulations compared to commercially available diacerein capsule Art®50. Comparative bioavailability studies conducted in healthy human volunteers revealed 1.7 fold and 1.2 fold rise in AUC0-6h for IR and GR formulations respectively, compared to Art®50 capsules. A Levy plot analysis comparing association between the time of in vitro dissolution (Tvitro) of diacerein and time of in vivo absorption (Tvivo) of rhein confirmed faster release and absorption from upper part of gastrointestinal region for both the optimized formulations.
    Current Drug Delivery 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: GLM-7 is a novel anti-leukemia drug in the pre-clinical study. The previous study shows that GLM-7 is a poorly water-soluble drug with the low oral bioavailability. In this study, we employed the self-emulsifying drug delivery system (SEDDS) to improve the oral bioavailability of GLM-7. The GLM-7 SEDDS formulation was prepared using MCT as oil, ovolecithin as surfactant and Transcutol as co-surfactant, and the formulation parameters were optimized by the response surface methodology. The optimized GLM-7 SEDDS formulation showed a stable liquid state, and can automatically emulsify to form the isotropic emulsion once exposure to the water phase. The generated emulsion showed the spherical shape, and had an average size of about 399nm and a zeta potential of about -42mV. Compared to the GLM-7 dissolution less than 1.4% from pure GLM-7 powder (reference), the GLM-7 SEDDS formulation could remarkably enhance the in vitro dissolution to 83% in the medium of 0.1N HCL. The in vivo oral bioavailability of GLM-7 SEDDS formulation was investigated in beagle dogs. The results demonstrated that the GLM-7 SEDDS formulation significantly enhanced the plasma concentrations of GLM-7, and the Cmax reached to 878ng/ml and was 9.2 folds as high as the Cmax 95.85ng/ml of reference. Moreover, the area under the curve (AUC) of GLM-7 SEDDS formulation was 13.6 times higher than that of reference, which suggested that the SEDDS formulation remarkably increased the oral bioavailability of GLM-7.
    Current Drug Delivery 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The hydrophobic long-chain dialkylcarbocyanine 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR) is an important near-infrared (NIR) fluorescent dye, which has a satisfactory photo stability for continuous excitation. During the past decade, it has been widely used for in vivo monitoring of cells. With the fast emergence of novel tumor-targeted nanocarriers, the applications of DiR in the development of fluorescent or multifunctional nano-probes for in vivo tumor imaging are also reported. In these studies, DiR-loaded nanocarriers have resulted in good fluorescence images, indicating the great potential of this dye. However, some important issues about DiR-loaded nanocarriers were often overlooked. These issues include the in vivo fluorescent properties, stability, toxicity, retention and metabolization of DiR-loaded nanocarriers. This review introduced the current use and the properties of DiR-loaded nanocarriers for in vivo tumor imaging. The perspective outlook at the last section highlights the future application of DiR-loaded nanocarriers.
    Current Drug Delivery 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coumarin class of organic compounds consist of 1,2-benzopyrone ring system as a basic parent scaffold. These benzopyrones are subdivided in to alpha-benzopyrones and gamma-benzopyrones; with coumarin class of compounds belongs to alpha-benzopyrones. From the last few years coumarins are synthesized in many of their derivatives forms. Their pharmacological, therapeutic and biochemical properties depend upon their pattern of substitution. Coumarins exhibit wide range of pharmacological activities, which includes anti-diabetic, anti-viral, anti-microbial, anti-cancer, anti-oxidant, anti-parasitic, anti-helminthic, anti-proliferative, anti-convulsant, anti-inflammatory and anti-hypertensive activities. Among these properties, the present review article compiles the detailed research findings of coumarins as anti-cancer agents. Research reports reveal that, coumarins inhibit human malignant tumor cell lines in vitro and also show anti-proliferative activity against many mammalian tumors in vivo. Clinical trials conducted on these coumarin class of compound showed promising activity against several types of cancer such as breast cancer, lung cancer, malignant melanoma, prostate cancer and metastatic renal cell carcinoma etc. This review presents a comprehensive and up to date literature survey on coumarins as anti-cancer agents. Furthermore, an overview of various clinical trials conducted on coumarin class of compounds tested for various types of malignancies has been detailed.
    Current Drug Delivery 07/2015; 12(1):1. DOI:10.2174/1567201812666150702102800
  • [Show abstract] [Hide abstract]
    ABSTRACT: Due to the effects of gastric acid, glycosidase and intestinal flora in the gastrointestinal environment, panax notoginseng saponins (PNS) can easily be resolved and metabolized when it is administered orally, limiting its oral bioavailability. The formula of PNS nanoemulsion (PNS-N) was optimized using a pseudoternary phase diagram, and the PNS-N was prepared by high pressure homogenization. The type, particle size, polydispersity index (PDI), refractive index, pH and content of PNS-N were characterized. In vitro characteristics were investigated by drug release and physical stability. The pharmacokinetic properties of PNS-N were studied with rat intestine and SD rats. The optimized nanoemulsion formulation was Labrafil M 1944CS (58%), SP/EtOH (Km=1) (25%), solution of PNS (400mg/ml) (17%). The results showed that the average particle size was (28.17±0.39) nm with PDI of 0.116±0.032, refractive index of 1.4491±0.0009 and pH of 4.58±0.03. In addition, the contents of R1, Rg1 and Rb1 were (4.64±0.21) mg/mL, (19.16±0.27) mg/mL and (11.77±0.08) mg/mL, respectively. The optimized PNS-N formulation exhibited a sustained drug release with good stability. PNS-N is still clear and transparent, without layering and precipitation after six months. In the study of absorption kinetics of PNS-N in rat intestine, the Papp of three main components of PNS-N increased 5 times than PNS solution (PNS-SOL) in rat intestine. And pharmacokinetic study in SD rats suggested a 2.58-fold increase of oral bioavailability compared with PNS-SOL. Therefore, the PNS-N has increased the absolute availability of PNS obviously.
    Current Drug Delivery 06/2015;